2023 / 06 / 30
Exhibition and Presentation at 25th INTERPHEX Week Tokyo
Ajinomoto Bio-Pharma Services will participate in 25th INTERPHEX Week Tokyo, on July 5 to 7, 2023.
INTERPHEX Week Tokyo is leading comprehensive pharma and cosmetics industry event in Asia. It consists of 4 exhibitions for pharmaceutical technologies – INTERPHEX JAPAN (Manufacturing & Packaging), in-PHARMA JAPAN (APIs/ Pharmaceutical Ingredients), BioPharma Expo (Biopharmaceutical) and PharmaLab Japan: formerly BIOtech Japan (Drug Discovery).
At the exhibit booth, we will introduce our innovative proprietary platform technologies, AJIPHASE®, AJICAP®, CORYNEX®, TALAMAX®.
In addition, we will present AJICAP®, CORYNEX® and TALAMAX®, and enzymatic oligonucleotide API production at exhibitor seminars and Special Session.
We look forward to your visit.
|Event Name||25th INTERPHEX Week Tokyo|
|Dates||July 5(Wed) – 7 (Fri), 2023|
|Venue||Tokyo Big Sight|
[Booth position] Booth number: 35-31
Exhibitors’ presentation 1
|Topics and Presenters||One-stop-shop service for peptide/protein manufacturing by AJINOMOTO’s unique expression platform technologies CORYNEX® and TALAMAX®
Kazuo Yamagishi, Ajinomoto healthy supply Co., Inc.
|Executive Summary||CORYNEX® is an endotoxin-free microbial secretory expression technology for the production of proteins, especially suitable for the production of VHH, antibody mimetics and long-chain peptides. In addition, we have developed a new technology to incorporate non-canonical amino acids at a site client choice in target protein, which enables the production of proteins that can conjugate with drugs and other substances.
TALAMAX® is a technology that enables the production of high-molecular-weight proteins such as antibodies, which have been difficult to produce using microorganisms.
In this presentation, we will introduce our one-stop-shop service from strain development to GMP manufacturing for client needs using our proprietary technologies.
|Date, Time and Venue||July 6(Thu) 10：50 – 11：20 【4】
Exhibitors’ presentation 2
|Topics and Presenters||Next generation antibody modification platform AJICAP® -Chemical site-specific conjugation & novel ADC linker technology-
Tomohiro Fujii, Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc.
|Executive Summary||Antibody-drug conjugates (ADCs) are promising biopharmaceuticals in which payload is added to an antibody. Recently, site-specific ADCs are expected to improve drug efficacy and reduce toxicity compared to existing random conjugated ADCs. In this presentation, we will introduce AJICAP®, a site-specific conjugation technology in ADC field.|
|Date, Time and Venue||July 6(Thu) 11：40 – 12：10 【4】
Inpharma Japan Special Session
|Topics and Presenters||Enzymatic Approach for Oligonucleotide Synthesis
Yusuke Hagiwara, Research Institute for Bioscience Products & Fine Chemicals, Senior Researcher,
|Executive Summary||The combination of the chemical synthesis of oligonucleotides and enzymatic conjugation is expected to improve the quality and productivity of oligonucleotide. We will introduce the development of enzymes for oligonucleotide production and process development studies in Ajinomoto Bio-Pharma Services.|
|Date, Time and Venue||July 5(Wed) 14:00 – 15:00 PI-S2